Analysis of SNP profiles in patients with major depressive disorder by Kõks, S. et al.
Analysis of SNP profiles in patients with
major depressive disorder
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Abstract
The present study focused on 91 single-nucleotide polymorphisms (SNPs) in 21 candidate genes to find
associations with major depressive disorder (MDD). In total, 160 healthy controls and 177 patients with
MDD were studied. We applied arrayed primer extension (APEX) based genotyping technology followed
by association and haplotype analysis. SNPs in CCKAR, DRD1, DRD2, and HTR2C genes showed nom-
inally significant associations with MDD. None of these associations remained significant after adjustment
for multiple testing. Haplotype analysis revealed CCKAR haplotypes to be associated with MDD (global
p=0.004). More precisely, we found the GAGT haplotype to be associated with increased risk for MDD
(OR 7.42, 95% CI 2.13–25.85, p=0.002). This haplotype effect remained significant after Bonferroni
correction (p=0.04 after Bonferroni’s adjustment). Altogether we were able to find some nominal
associations, but due to small sample size these results should be taken as exploratory. However, the effect
of GAGT haplotype on the CCKAR gene may be considered as increasing the risk for MDD.
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Introduction
Mood disorders are among the most prominent causes
of disability and the second leading source of disease
burden (Merikangas et al., 2002 ; Murray and Lopez,
1996). Most epidemiological and family studies indi-
cate that the lifetime prevalence of unipolar major
depressive disorder (MDD) is between 5% and 10%
(Moldin et al., 1991). Suicide has been reported to
occur in 10–15% of patients previously hospitalized
for depression, a rate of death that is three orders of
magnitude greater than that reported for the American
population as a whole (Angst et al., 1999 ; Zubenko
et al., 2002). Therefore, MDD is obviously a serious
problem for public health.
Family and twin studies demonstrate that genetic
factors typically account for 40–50% of the risk for
developing MDD (McGuffin et al., 1996). A large
number of family studies have demonstrated an
increased risk of MDD among relatives of MDD pro-
bands, with y2-fold increased risk in first-degree
relatives (Kupfer et al., 1989 ; McGuffin et al., 1991).
However, several reports do not support so high
genetic risk for MDD, indicating the importance of
environmental factors (Sullivan et al., 2000).
The aim of our study was to screen a set of single-
nucleotide polymorphisms (SNPs) for their association
with MDD. We defined the genes and their variations
which have been previously published in the literature
and yielded some (although inconsistent) significant
findings, as candidate genes in our study. Genes
related to the following neurotransmitter systems
were included in the present survey: cholecystokinin
(CCK), opioid peptides (OP), serotonin (5-HT) and
dopamine (DA). CCK has been extensively studied as
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Table 1. Description of single-nucleotide polymorphisms (SNPs) analysed in our study
Gene name
(abbreviation) Gene and SNP
Position
from ATG Location db SNP rs # Allele 1 Allele 2 Function
Allele 1
frequency
Cholecystokinin CCK x45 CCK x1172 3p22–p21.3 rs1799923 C T 5k-UTR 0.89
(CCK) CCK 1270 CCK x9 3p22–p21.3 rs754635 C G 5k-UTR 0.85
CCK 6662 CCK 5386 3p22–p21.3 rs3774396 C T intron 0.98
Cholecystokinin A CCKAR x128 CCKAR x333 4p15.1–p15.2 rs1800908 G T 5k-UTR 0.96
receptor (CCKAR) CCKAR 201 CCKAR x286 4p15.1–p15.2 rs1799723 A G 5k-UTR 0.94
CCKAR 246 CCKAR x241 4p15.1–p15.2 rs # n.a. G A 5k-UTR 0.97
CCKAR 608 CCKAR 122 4p15.1–p15.2 rs1800856 G A intron 0.96
CCKAR 1260 CCKAR 773 4p15.1–p15.2 rs1800855 T A intron 0.71
CCKAR 1266 CCKAR 779 4p15.1–p15.2 rs1800857 T C intron 0.76
CCKAR 3849 CCKAR 8231 4p15.1–p15.2 rs1805037 C T I296I 0.99
Cholecystokinin B CCKBR x215 CCKBR x216 11p15.4 rs1799721 C A 5k-UTR 0.95
receptor (CCKBR) CCKBR 109 CCKBR 109 11p15.4 rs1805000 C T L37F 0.93
CCKBR 1550 CCKBR 9962 11p15.4 rs1805002 G A V125I 0.92
CCKBR 2491 CCKBR 10907 11p15.4 rs1800843 C A Intron 0.88
rs8192470
Dopamine receptor DRD1 x2218 DRD1 x2218 5q35.1 rs # n.a. T C 5k-UTR 0.94
D1 (DRD1) DRD1 x2102 DRD1 x2102 5q35.1 rs # n.a. C A 5k-UTR 0.93
DRD1 x2030 DRD1 x2030 5q35.1 rs # n.a. T C 5k-UTR 0.97
DRD1 x1251 DRD1 x1252 5q35.1 rs # n.a. G C 5k-UTR 0.86
DRD1 x800 DRD1 x800 5q35.1 rs265981 T C 5k-UTR 0.38
DRD1 x94 DRD1 x94 5q35.1 rs5326 G A 5k-UTR 0.84
DRD1 x48 DRD1 x48 5q35.1 rs4532 G A 5k-UTR 0.44
Dopamine receptor DRD2 x241 DRD2 x50978 11q23 rs1799978 A G 5k-UTR 0.78
D2 (DRD2) DRD2 x141 DRD2 x50878 11q23 rs1799732 C del 5k-UTR 0.84
DRD2 x7054 DRD2 x7053 11q23 rs # n.a. C A 5k-UTR 0.92
DRD2 x913 DRD2 x913 11q23 rs1079597 A G 5k-UTR 0.32
DRD2 x901 DRD2 x901 11q23 rs1079598 C T 5k-UTR 0.32
DRD2 286 DRD2 287 11q23 rs # n.a. T C intron 0.93
DRD2 3625 DRD2 3626 11q23 rs2734834 A T intron 0.49
DRD2 3785 DRD2 3786 11q23 rs1800498 C T intron 0.39
DRD2 11924 DRD2 11890 11q23 rs1801028 C G S311C 0.93
DRD2 11997 DRD2 11915 11q23 rs6277 T C P319P 0.94
DRD2 16893 DRD2 16891 11q23 rs2234689 C G 3k-UTR 0.72




Dopamine receptor DRD3 x707 DRD3 x710 3q13.3 rs1800828 G C 5k-UTR 0.71
D3 (DRD3) DRD3 x343 DRD3 x346 3q13.3 rs1800827 G A 5k-UTR 0.96
DRD3 25 DRD3 25 3q13.3 rs6280 A G G9S 0.69
Dopamine receptor DRD4 x1217 DRD4 x1216 11p15.5 rs # n.a. G del 5k-UTR 0.62
D4 (DRD4) DRD4 x809 DRD4 x808 11p15.5 rs936461 G A 5k-UTR 0.80
DRD4 x768 DRD4 x767 11p15.5 rs4987058 G A 5k-UTR 0.86
DRD4 x616 DRD4 x615 11p15.5 rs747302 C G 5k-UTR 0.68
DRD4 x521 DRD4 x521 11p15.5 rs1800955 C T 5k-UTR 0.41
DRD4 x376 DRD4 x376 11p15.5 rs916455 C T 5k-UTR 0.96
Dopamine receptor
D5 (DRD5)
DRD5 1481 DRD5 1481 4p16.1 rs1967551 C T 3k-UTR 0.65
Tyrosine hydroxylase TH 241x243 TH 2066 11p15.5 rs6356 G A V81M 0.61
(TH) TH 614 TH 3891 11p15.5 rs # n.a. T C L205P 0.96
5-hydroxytryptamine HTR1A x1018 HTR1A x1019 5q11.2–q13 rs6295 C G 5k-UTR 0.43
(serotonin) receptor
1A (HTR1A)
HTR1A x480 HTR1A x480 5q11.2–q13 rs # n.a. A del 5k-UTR 0.91
5-hydroxytryptamine HTR1B HTR1B x1089 6q13 rs1778258 T C 5k-UTR 0.24













(abbreviation) Gene and SNP
Position
from ATG Location db SNP rs # Allele 1 Allele 2 Function
Allele 1
frequency
(serotonin) receptor HTR1B HTR1B x700 6q13 rs1228814 C A 5k-UTR 0.55
1B (HTR1B) HTR1B x511 HTR1B x511 6q13 rs130056 G T 5k-UTR 0.995
HTR1B x161 HTR1B x161 6q13 rs130058 A T 5k-UTR 0.78
HTR1B 129 HTR1B 129 6q13 rs6298 C T S43S 0.74
HTR1B 276 HTR1B 276 6q13 rs130059 G A A92A 0.96
HTR1B 371 HTR1B 371 6q13 rs130060 T G F124C 0.99
HTR1B 705 HTR1B 705 6q13 rs130062 C T A235A 0.80
HTR1B 861 HTR1B 861 6q13 rs6296 G C V287V 0.74
HTR1B HTR1B 1180 6q13 rs6297 G A 3k-UTR 0.23
5-hydroxytryptamine HTR2A x1438 HTR2A x1437 13q14–q21 rs6311 A G 5k-UTR 0.42
(serotonin) receptor HTR2A 73 HTR2A 74 13q14–q21 rs1805055 C A T25N 0.98
2A (HTR2A) HTR2A 102 HTR2A 102 13q14–q21 rs6313 T C S34S 0.37
HTR2A 1354 HTR2A 61008 13q14–q21 rs6314 C T H452Y 0.94
5-hydroxytryptamine HTR2C 68 HTR2C 4390 Xq24 rs6318 G C C23S 0.83
(serotonin) receptor
2C (HTR2C)
HTR2C 2831 HTR2C 181359 Xq24 rs1801412 T G 3k-UTR n.a.
5-hydroxytryptamine HTR3A 1302 HTR3A x507 11q23.1–q23.2 rs1150226 T C 5k-UTR 0.31
(serotonin) receptor
3A (HTR3A)
HTR3A 1596 HT3A 14378 11q23.1–q23.2 rs1176713 G A L459L 0.26
Solute carrier family SLC6A4 SLC6A4 18784 17q11.1–q12 rs6352 A C K605N 0.96




SLC6A4 SLC6A4 167 17q11.1–q12 rs6355 G C G56A 0.77





TPH1 779 TPH1 15055 11p15.3–p14 rs1799913 A C intron 0.27
Opioid receptor, mu 1 OPRM1 31 OPRM1 50665 6q24–q25 rs # n.a. G A intron 0.92
(OPRM1) OPRM1 118 OPRM1 118 6q24–q25 rs1799971 A G N40D 0.78
OPRM1 440 OPRM1 50431 6q24–q25 rs # n.a. C G S147C 0.84
OPRM1 691 OPRM1 51325 6q24–q25 rs2075572 C G intron 0.54
Opioid receptor, OPRD1 80 OPRD1 80 1p36.1–p34.3 rs1042114 T G C27F 0.91
delta 1 (OPRD1) OPRD1 921 OPRD1 50702 1p36.1–p34.3 rs2234918 T C G307G 0.63
Opioid receptor, OPRK1 36 OPRK1 36 8q11.2 rs1051660 G T P12P 0.84
kappa 1 (OPRK1) OPRK1 OPRK1 10807 8q11.2 rs1365097 A G intron 0.69
OPRK1 OPRK1 10915 8q11.2 rs1365098 G T intron 0.66
OPRK1 OPRK1 11220 8q11.2 rs997917 A G intron 0.54
OPRK1 459 OPRK1 16128 8q11.2 rs7815824 C T S153S 0.90
OPRK1 843 OPRK1 21441 8q11.2 rs702764 A G A281A 0.72
OPRK1 846 OPRK1 21444 8q11.2 rs # n.a. C T V282V 0.97
Proopiomelanocortin POMC 18 POMC 18 2p23.3 rs8192605 C T C6C 0.99
(POMC) POMC 282 POMC 3170 2p23.3 rs # n.a. C T S94S 0.92
POMC 313 POMC 3201 2p23.3 rs # n.a. G T E105Stop 0.96
POMC 346 POMC 3234 2p23.3 rs # n.a. C T L116L 0.98
POMC 585 POMC 3473 2p23.3 rs2071345 C T A195A 0.94
POMC 866 POMC 3755 2p23.3 rs1042571 C T 3k-UTR 0.85
Proenkephalin PENK 28 PENK x588 8q23–q24 rs2609999 C A 5k-UTR 0.57
(PENK) PENK 808 PENK 4686 8q23–q24 rs3839874 C del 3k-UTR 0.67
db SNP rs # – accession number of SNP in NCBI dbSNP database ; allele frequency is based on controls of this study. rs #
n.a. – SNP is not listed in NCBI dbSNP database (http ://www.ncbi.nlm.nih.gov/SNP/).
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a gene involved in the pathogenesis of emotional dis-
orders, especially anxiety and panic disorders (Bowen
et al., 1998 ; Geracioti et al., 1989 ; Hattori et al., 2002;
Kennedy et al., 1999b). Opioid peptides are also
implicated in the development of emotional disorders
(Alda et al., 2000 ; Peckys and Hurd, 2001). As proopio-
melanocortin (POMC) is a precursor for adrenocor-
ticotropin hormone (ACTH) and patients with mood
disorders have disturbances in the hypothalamic–
pituitary–adrenal (HPA) system, POMC is a good
target for association studies (Galard et al., 2002). 5-HT
and DA are monoamines which are frequently studied
in respect to mood disorders (Nutt, 2002 ; Pania and
Gessab, 2002). Genes of the above described neuro-
transmitters and their receptors were chosen for geno-
typing. Altogether we analysed 91 polymorphisms
located in 21 candidate genes (detailed information
about the studied polymorphisms is available in
Table 1). SNP analysis was performed by arrayed
primer extension (APEX) technology. APEX is a geno-
typing and resequencing technology that combines
Sanger dideoxy sequencing with the parallelization
and high-throughput potential of microarray format
(Tõnisson et al., 2002). APEX technology is suitable for
SNP analysis allowing the screening of hundreds of
SNPs in one sample.
Methods
Subjects and psychiatric assessment
Unrelated patients (n=177; 39 male, 138 female ; age
range 18–73 yr ; mean age 40.3 yr) with MDD were
recruited in the study along with healthy control
individuals (n=160; 49 male, 111 female ; age range
18–71 yr ; mean age 37.7 yr) from the Estonian
population. Diagnoses of patients were substantiated
by psychiatric interview and verified by Mini
International Neuropsychiatric Interview (M.I.N.I.
5.0.0) based on DSM-IV (Sheehan et al., 1998). The case
group consisted of patients with only MDD (n=69)
and MDD patients with comorbid anxiety disorders
[panic disorder, generalized anxiety disorder (GAD),
obsessive–compulsive disorder (OCD), social phobia]
(n=108). Controls were evaluated using M.I.N.I. to
exclude those with psychiatric morbidity, and with
a family history interview to exclude those with a
known history of major psychiatric disorders in first-
degree relatives. Patients were recruited among con-
secutive outpatients and in-patients at the Clinic of
Psychiatry of Tartu University Clinics and controls
were recruited by newspaper advertisement in Tartu,
Estonia. The study was conducted in accordance with
the principles of the Declaration of Helsinki. The study
protocol was approved by the Ethics Review
Committee on Human Research of the University of
Tartu. Each subject provided written informed con-
sent.
Template preparation and genotyping
Standard high-salt extraction method was used to
isolate genomic DNA from 9 ml venous blood
samples. Two different PCR programs were used to
amplify the genomic regions containing the whole set
of studied 91 polymorphisms with 64 individual PCR
reactions. In program 1 amplification reactions con-
sisted of an initial 5 min denaturation at 95 xC, fol-
lowed by 34 cycles of : 95 xC for 30 s, 55 xC for 40 s,
72 xC for 40 s. The final extension step was 72 xC for
6 min. Program 2 contained temperature decrements
of 1 xC per cycle in annealing step for first 10 cycles.
Samples were processed in a PTC-200 thermal cycler
(MJ Research Inc., Watertown, MA, USA). Primer
sequences and PCR conditions used for amplification
are available upon request.
A 20% fraction of the dTTP in the amplification
mixture was substituted by dUTP, allowing later
fragmentation of PCR products with uracil-N-glyco-
sylase. Pooled amplification products were concen-
trated and purified, followed by fragmentation and
functional inactivation of the unincorporated dNTPs
as described in Tõnisson et al. (2002). Production of
oligonucleotide microchips and APEX reactions were
performed as described earlier (Tõnisson et al., 2002).
Slides were imaged with Genorama Quattroimager
detector (Asper Biotech Ltd, Tartu, Estonia) and
polymorphisms were identified by GenoramaTM 4.1
genotyping software (Asper Biotech Ltd) by using
signal patterns from a wild-type DNA sequence as the
reference.
Selection of SNPs
By choosing missense SNPs for genotyping, we
reasoned that at least some of them are probably
causative mutations affecting function of the encoded
protein associated with the underlying phenotype. We
included common synonymous SNPs in our study
under the assumption that silent SNPs, being in link-
age disequilibrium (LD) with unknown functional
polymorphism, can reveal an association with the
actual disease-causing SNP(s). SNPs in regulatory
sequences are thought to have the potential to control
the level of gene expression, therefore, in some genes
polymorphisms in 5k or 3k untranslated regions and
intronic SNPs were included.












Association analysis statistics was performed using
GENEPOP Version 3.3 software (Raymond and Rousset,
1995). p values for allelic and genotypic association
were calculated using Fisher’s exact test. The signifi-
cance level for all statistical tests was 0.05. Haplo-
type analysis was performed using the maximum-
likelihood method for estimating simultaneously
haplotype frequencies and haplotype–phenotype
association as described in Tregouet et al. (2002).
Pairwise LD was estimated by a log-linear model and
the extent of disequilibrium was expressed in terms of
standardized Dk characteristic. Bonferroni correction
was used after association and haplotype analysis to
adjust for multiple testing.
Results
We genotyped 91 polymorphisms (87 SNPs and 4
insertions/deletions) in 21 candidate genes in 177
unrelated MDD patients and 160 healthy controls. In
our screening set, genetic variations in altogether four
genes displayed association with MDD. Data for
statistically significant SNPs are presented in Table 2.
Namely, SNPs 246G/A in CCKAR, x2102C/A in
DRD1, x7054C/A in DRD2, and 68G/C (rs6318) in
HTR2C genes were associated with MDD. In the case
of CCKAR and DRD2 markers an excess of minor
alleles in the affected group was found. In contrast, the
minor alleles of DRD1 and HTR2Cmarkers were more
frequent in control subjects. After Bonferroni correc-
tion, none of the describedmarker-disease associations
remained statistically significant. There was no devi-
ation from Hardy–Weinberg equilibrium expectations
at any of the genotyped loci. A gender comparison
between females (n=139) and males (n=38) of the
MDD sample did not show any significant differences
with regard to alleles and/or genotypes. Our data in-
dicate that the relationship between unipolar affective
disorder and analysed loci appear to be independent
of sex. Haplotype analysis was performed according
to particular pairwise LDpattern for each gene (cases+
controls, n=337). Only genes that were genotyped for
two or more SNPs and showing the presence of LD
in both affected and control groups, and having pre-
liminary evidence of marker-disease association were
included in haplotype analysis. It was also possible to
investigate the effect of each SNP on different haplo-
typic background using the inference method. The
odds ratio for MDD was estimated according to the
haplotypic background conferred by other poly-
morphisms. Haplotype analysis revealed CCKAR
haplotypes to be associated with MDD and altogether
six haplotypes (HT) were found (Table 3). Reference
haplotypes combined with the major alleles at each
locus, which taken together with another common
haplotype constituted almost 90% of all alleles. Both
haplotypes were almost equally represented in cases
and control subjects. Other haplotypes were rare.
Haplotype 3 (GAGT) was significantly over-
represented in the affected group, reflecting a higher
frequency of the rare 246A allele in cases by compari-
son to the reference haplotype (GGGT). This haplo-
type (GAGT) was associated with a higher risk for
MDD (OR 7.42, 95% CI 2.13–25.85, p=0.002) com-
pared to the reference haplotype (GGGT). This haplo-
type effect also remained significant after Bonferroni
correction (p=0.04 after Bonferroni’s adjustment). We
detected a significant individual SNP effect (OR 7.40,
p=0.002) for 246G/A in a haplotype context HT1
(GGGT) vs. HT3 (GAGT). The test of a global CCKAR
haplotypic association with MDD was significant in
the population studied (x2 =17.60, d.f.=5, p=0.004).
Taken together, results of haplotype analysis con-
firmed our findings from the association study.
Haplotype analysis revealed that CCKAR haplotype
(GAGT) formed by SNPs at positions x128G/T
(rs1800908), 246G/A, 608G/A (rs1800856), and 1266T/
C (rs1800857) is a possible susceptibility haplotype for
MDD.
Discussion
Clinical as well as molecular genetic studies indicate
that MDD is a polygenic disorder. Many genes, each of
minor individual contribution, are likely to be
involved in the development of affective disorders.
In our screening set of 91 polymorphisms in 21 candi-
date genes, variations in four genes displayed an
association with MDD. Polymorphisms in CCKAR
Table 2. Results of association analysis of 91






1 2 MDD MDD Controls
246 G A CCKAR 0.006 0.09 0.03
x2102 C A DRD1 0.008 0.02 0.07
x7054 C A DRD2 0.03 0.14 0.08
68 G C HTR2C 0.02 0.10 0.17
SNP, single-nucleotide polymorphism; MDD, major
depressive disorder.
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(246G/A), DRD1 (x2102C/A), DRD2 (x7054C/A),
and HTR2C (68G/C, rs6318) genes were associated
with MDD phenotypes.
Pharmacological studies have suggested that MDD
is associated with impairment of brain monoaminergic
transmission (Nemeroff, 2002). The role of 5-HT in the
pathology of mood disorders is based mainly on
the efficacy of selective 5-HT reuptake inhibitors in the
treatment of MDD. DA has also been implicated in the
pathophysiology of mood disorders and hypoactivity
of the mesolimbic DA pathway may be related to de-
pressive symptoms. Thus, genes that control the brain
5-HT and DA pathways seem to be good candidates
for mediating genetic susceptibility to MDD.
Association of CCKAR gene polymorphism with
MDD was further confirmed by haplotype analysis,
where the GAGT haplotype carrying the risk for MDD
(OR 7.418, p=0.002) was established. CCKAR poly-
morphisms have been shown to be involved in
schizophrenia and auditory hallucinations (Wang et
al., 2002 ; Wei and Hemmings, 1999), and also in panic
disorder (Miyasaka et al., 2004). Preclinical studies
suggest that CCKAR directly regulates the release
of DA in the nucleus accumbens and amygdala
(Hamilton and Freeman, 1995). Therefore, CCKAR is
implicated in the regulation of emotional behaviour
and motivation. Supportive evidence of CCKAR gene
involvement in mood disorders is also related to its
genomic localization (4p15.1–p15.2). This locus is close
to the 4p16 region which has been repeatedly shown to
be related to bipolar disorder (Kennedy et al., 1999a).
In our previous study we found that polymorphisms
in the wolframin (WFS1) gene, also located in the 4p16
region, are possibly related to an increased risk for
mood disorders (Koido et al., 2004). This study sample
was partially the same as in the present study. Als and
colleagues found that markers in the 4p15 region
appeared to be associated with schizophrenia and
schizophrenia combined with bipolar disorder, and
also supportive evidence for schizophrenia and
bipolar disorder being associated with the 4p16 region
(Als et al., 2004). Therefore, the 4p15–p16 region
seems to be a good candidate risk locus for psychiatric
disorders.
Results of this study provide further evidence for
the involvement of genes related to monoaminergic
and peptidergic neurotransmission in the regulation
of mood disorders. However, we cannot exclude a
hypothesis describing polymorphisms as being in LD
with other functionally significant polymorphisms,
which could actually be involved in mood disorders. It
has been shown that missense SNP itself probably
does not cause disease but it is in strong LD with non-
functional SNP which may actually contribute to the
susceptibility for disease (Handoko et al., 2004). This
warrants studying not only functional polymorphisms
but also untranslated SNPs.
Due to the limited size of our sample this study
should be considered an exploratory in nature. A
multi-stage approach is recommended to distinguish
false-positive discoveries from real associations
(Hirschhorn and Daly, 2005). As many association
studies produce unreplicable results due to false-
positive findings induced by multiple testing, it is
suggested that first, many markers should be typed for
a subset of individuals. Afterwards the most promis-
ing markers can be evaluated on a larger sample (van
den Oord and Sullivan, 2003). Therefore, replication
studies with larger and independent samples are
needed.
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